LAVA Therapeutics Past Earnings Performance
Past criteria checks 0/6
LAVA Therapeutics's earnings have been declining at an average annual rate of -12.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 20.8% per year.
Key information
-12.1%
Earnings growth rate
88.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 20.8% |
| Return on equity | -56.4% |
| Net Margin | -326.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How LAVA Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 7 | -24 | 11 | 24 |
| 31 Mar 24 | 13 | -29 | 12 | 30 |
| 31 Dec 23 | 7 | -42 | 13 | 34 |
| 30 Sep 23 | 9 | -50 | 14 | 1 |
| 30 Jun 23 | 24 | -41 | 14 | 47 |
| 31 Mar 23 | 20 | -36 | 14 | 43 |
| 31 Dec 22 | 19 | -32 | 14 | 40 |
| 30 Sep 22 | 18 | -25 | 14 | 30 |
| 30 Jun 22 | 5 | -33 | 15 | 16 |
| 31 Mar 22 | 5 | -32 | 15 | 7 |
| 31 Dec 21 | 5 | -42 | 12 | 37 |
| 30 Sep 21 | 6 | -37 | 9 | 0 |
| 30 Jun 21 | 5 | -34 | 6 | 0 |
| 31 Mar 21 | 5 | -31 | 4 | 0 |
| 31 Dec 20 | 4 | -16 | 3 | 0 |
Quality Earnings: 4PKB is currently unprofitable.
Growing Profit Margin: 4PKB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4PKB is unprofitable, and losses have increased over the past 5 years at a rate of 12.1% per year.
Accelerating Growth: Unable to compare 4PKB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4PKB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 4PKB has a negative Return on Equity (-56.4%), as it is currently unprofitable.